A systematic review of historical and current trends in Chagas disease

Diego-Abelardo Álvarez-Hernández, Rodolfo García-Rodríguez-Arana, Alejandro Ortiz-Hernández, Mariana Álvarez-Sánchez, Meng Wu, Rojelio Mejía, Luis-Alberto Martínez-Juárez, Alejandra Montoya, Héctor Gallardo-Rincon, Rosalino Vázquez-López and Ana-María Fernández-Presas

Abstract

Introduction: Chagas disease (CD) is caused by Trypanosoma cruzi. When acquired, the disease develops in stages. For diagnosis, laboratory confirmation is required, and an extensive assessment of the patient’s health should be performed. Treatment consists of the administration of trypanocidal drugs, which may cause severe adverse effects. The objective of our systematic review was to analyze data contained in the CD published case reports to understand the challenges that patients and clinicians face worldwide.

Materials and methods: We performed a systematic review following the PRISMA guidance. PubMed database was explored using the terms ‘American trypanosomiasis’ or ‘Chagas disease’. Results were limited to human case reports written in English or Spanish. A total of 258 reports (322 patients) were included in the analysis. Metadata was obtained from each article. Following this, it was analyzed to obtain descriptive measures.

Results: From the sample, 56.2% were males and 43.8% were females. Most cases were from endemic countries (85.4%). The most common clinical manifestations were fever during the acute stage (70.0%), dyspnea during the chronic stage in its cardiac form (53.7%), and constipation during the chronic stage in its digestive form (73.7%). Most patients were diagnosed in the chronic stage (72.0%). Treatment was administered in 56.2% of cases. The mortality rate for the acute stage cases was 24.4%, while for the chronic stage this was 28.4%.

Discussion: CD is a parasitic disease endemic to Latin America, with increasing importance due to human and vector migration. In this review, we report reasons for delays in diagnosis and treatment, and trends in medical practices. Community awareness must be increased to improve CD’s diagnoses; health professionals should be appropriately trained to detect and treat infected individuals. Furthermore, public health policies are needed to increase the availability of screening and diagnostic tools, trypanocidal drugs, and, eventually, vaccines.

Keywords: American trypanosomiasis, Chagas disease, myocardiopathy, neglected tropical diseases, Trypanosoma cruzi

Received: 18 December 2020; revised manuscript accepted: 1 July 2021.

Introduction

American trypanosomiasis, or Chagas disease (CD), is a parasitic disease caused by infection with the hemoflagellate protozoan Trypanosoma cruzi (T. cruzi).¹ It is recognized by the World Health Organization (WHO) as a Neglected Tropical Disease (NTD).² NTDs are a group of infectious and non-infectious diseases that are prevalent in tropical and subtropical environments. They mainly affect poor and marginalized communities with little visibility and little political voice.³ While endemic to Latin America, CD can now be found in immigrant populations worldwide. CD can be transmitted to humans by
several different pathways; it poses a challenge to health professionals and health systems that are unprepared to diagnose and treat the disease. The objective of our systematic review was to analyze the data contained in the CD published case reports to understand the challenges that CD patients experience and the practices of CD clinicians worldwide.

Materials and methods

Search strategies

A systematic review was performed following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidance. The PubMed database was explored using the search terms ‘American trypanosomiasis’ or ‘Chagas disease.’ The results were filtered to include full-text case reports of humans with CD, written in English or Spanish. A total of 456 records were obtained during the initial search. Two reviewers screened the titles and abstracts to determine if they met the inclusion criteria. During the screening, 35 records were excluded: 19 that could not be accessed or tracked, 14 that were not a case report, and 2 that were duplicated. A total of 421 records proceeded to the full-text assessment. Four reviewers assessed the content of the case reports to determine if they had enough information about the patients and their disease. During the assessment, 163 records were excluded: 74 that did not contain enough information of the patients, 65 that did not mention CD at all (Chagas was the surname of an author, or part of the name of its workplace), 22 that mentioned CD as a possible diagnosis, and 2 that only mentioned CD as a comorbidity. A total of 258 records describing the information of 322 patients were included in the analysis (Table 1). For quality assurance, another pair of reviewers randomly selected 10% of the case reports and assessed their consistency. No other records were excluded. The complete selection process can be consulted in Figure 1.

Table 1. Number of patients contained in each Chagas Disease case report.

| Number of descriptions | Number of case reports | Number of patients | Percentage of the sample |
|------------------------|------------------------|--------------------|--------------------------|
| 1                      | 228                    | 228                | 70.8                     |
| 2                      | 13                     | 26                 | 8.0                      |
| 3                      | 9                      | 27                 | 8.3                      |
| 4                      | 4                      | 16                 | 4.9                      |
| 5                      | 2                      | 10                 | 3.1                      |
| 7                      | 1                      | 7                  | 2.1                      |
| 8                      | 1                      | 8                  | 2.4                      |

Data extraction

Each case report was read and predefined variables were extracted, including:

- **Publishing data**: Main author surname and year of publication.
- **Demographic data**: Sex, age, country, and state of origin.
- **Mechanism of transmission**: Vector-borne transmission, blood transfusion, bone marrow transplant, organ transplant, congenital transmission, oral transmission, or accidental exposure.
- **Clinical manifestations**: General: Dizziness, fatigue, weakness, asthenia, adynamia, myalgia, arthralgia, fever, headache, lymph node enlargement (LNE), diaphoresis, and dehydration.
- **Respiratory**: Dyspnea, orthopnea, paroxysmal nocturnal dyspnea (PND), tachypnea, cough, and crackles.
- **Cardiovascular**: Syncope, jugular vein distention (JVD), edema, palpitations, chest pressure, bradycardia, tachycardia, heart murmur, irregular pulse, and high blood pressure (HBP).
- **Gastrointestinal**: Weight loss, hyporexia, nausea, vomiting, dysphagia, regurgitation, abdominal pain, distension, constipation, diarrhea, ascites, hepatomegaly, and splenomegaly.
- **Neurological**: Neurological impairment, seizures, hemiparesis, hemiplegia, facial palsy, ataxia, aphasia, and Babinski reflex.
- **Dermatological**: Dermatoses.
- **CD diagnostic criteria**: Acute stage diagnosis: Direct blood examination, blood smear, Strout test, microhematocrit, xenodiagnoses, blood
culture, and polymerase chain reaction (PCR).

- **Chronic stage diagnosis:** Enzyme-linked immunosorbent assay (ELISA), indirect immunofluorescence (IIF), hemagglutination inhibition assay (HAI), immunochromatographic test (ICT), chemiluminescent microparticle immunoassay (CMIA), radioimmuno-precipitation assay (RIPA), immunoblot (IB), and complement fixation test (CFT).

- **Complimentary assessments:**
  - **Cardiovascular involvement:** Chest X-ray, electrocardiogram (ECG), and echocardiogram with their abnormal findings.
  - **Gastrointestinal involvement:** Abdominal X-ray, barium swallow, barium enema, abdominal ultrasound, abdominal computerized tomography (CT), endoscopy, and colonoscopy with their abnormal findings.
  - **Neurological involvement:** Head CT with its abnormal findings.

- **Stage and substage of the disease:** Acute or chronic (chronic asymptomatic, chronic symptomatic with cardiac, digestive, or cardio digestive forms, or reactivation of the disease).

---

**Figure 1.** PRISMA flow diagram of the systematic review.
• **Trypanocidal treatment**: Benznidazole or nifurtimox.
• **Surgical management**: Type of surgery.
• **Histopathology**: Tissue or organ biopsy and absence or presence of amastigotes nests.
• **Outcome**: Alive or death and cause of death.

A spreadsheet was built using Excel® from Microsoft Office 360® for data synthesis.

**Statistical analysis**
The Excel® from Microsoft Office 360® spreadsheet was exported to SPSS Statistics® software version 26 from IBM Corporation® to obtain descriptive measures of frequency, tendency, and dispersion, according to the characteristics of each variable.

**Results**

**Demographic data**
Of the 322 cases, 181 (56.2%) were males and 141 (43.8%) were females. The mean age of presentation was 37.7 years (± standard deviation (SD) 19.6).

**Geographic data**
A total of 275 (85.4%) cases were reported in endemic countries, while 47 (14.6%) were reported in non-endemic countries. From the endemic countries, Brazil had the most with 104 (32.3%) cases, followed by Argentina with 48 (14.9%), and Bolivia with 26 (8.1%). Of the non-endemic countries, the United States (US) had the most with 29 (9.0%) cases, followed by Spain with 8 (2.5%), and Canada with 4 (1.2%). The global distribution can be found in Figure 2.

**Mechanism of transmission**
The mechanism of transmission was known in 125 (38.8%) cases and unknown in 197 (61.2%). From the cases in which the mechanism of transmission was acknowledged, oral transmission was the most common route, with 31 (24.8%), followed by organ transplantation and vector-borne transmission with 29 (23.2%), congenital transmission with 23 (18.4%), blood transfusion with 9 (7.2%), and accidental exposure with 4 (3.2%).

Additional information regarding the mechanism of transmission was obtained for:
• **Oral transmission**: Bacaba juice was involved in CD transmission in 10 (32.3%) cases, and açai juice in 6 (19.4%). The food or juice was not specified in the other 15 (48.4%).
• **Organ transplantation**: The heart and kidneys were involved in the transmission of CD in 10 (34.5%) cases, the bone marrow in 5 (17.2%), the liver in 3 (10.3%), and the pancreas in 1 (3.4%).

**Clinical manifestations**
The most common clinical manifestations by stage and substage of the disease were:

- **Acute stage**: Fever was described in 63 (70.0%) cases, dermatoses in 28 (31.1%), edema in 26 (28.9%), headache and hepatomegaly in 23 (25.6%), myalgia in 22 (24.4%), dyspnea in 20 (22.2%), and LNE, tachycardia, and abdominal pain in 16 (17.8%).
- **Chronic stage**:
  - **Indeterminate stage**: Dermatoses and splenomegaly were reported in 3 (10.0%) cases, arthralgia, HBP, and hepatomegaly in 2 (6.7%), and neurological impairment, adynamia, myalgia, headache, LNE, weight loss, cough, tachycardia, vomiting, abdominal pain, and constipation in 1 (3.3%).
  - **Determinate stage**:
    - **Cardiac form**: Dyspnea was described in 44 (53.7%) cases, chest pressure in 35 (42.7%), edema in 27 (32.9%), palpitations in 26 (31.7%), JVD in 24 (29.3%), orthopnea in 23 (28.0%), syncope in 21 (25.6%), PND in 17 (20.7%), heart murmur in 16 (19.5%), and neurological impairment and crackles in 12 (14.6%).
    - **Digestive form**: Constipation was reported in 14 (73.7%) cases, dysphagia in 7 (36.8%), abdominal pain in 6 (31.6%), weight loss and distention in 5 (26.3%), dehydration in 4 (21.1%), nausea, vomiting and regurgitation in 3 (15.8%), and crackles and tachycardia in 2 (10.5%).
Cardio digestive form: Constipation was described in 7 (41.2%) cases, dyspnea in 6 (35.3%), abdominal pain in 5 (29.4%), and neurologic impairment, edema, orthopnea, syncope, chest pressure, heart murmur, dysphagia, and distention in 4 (23.5%).

Reactivation of the disease: Fever was reported in 47 (56.0%) cases, neurological impairment in 37 (44.0%), hemiparesis in 25 (29.8%), headache in 20 (23.8%), seizures and dyspnea in 19 (23.8%), dermatoses in 17 (20.2%), weight loss and chest pressure in 16 (19.0%), and palpitations in 14 (16.7%).

Laboratory tests
Diagnostic acute stage tests were performed in 187 (58.1%) cases, while diagnostic chronic stage tests were performed in 261 (81.1%). The dataset was filtered to identify the most ordered diagnostic tests in each stage:

- **Acute stage tests**: A PCR was ordered in 98 (30.4%) cases, blood smear in 69 (21.4%), blood culture in 62 (19.3%), direct blood examination in 39 (12.1%), xenodiagnoses in 34 (10.6%), microhematocrit in 16 (5.0%), and Strout test in 9 (2.8%). The proportion of positive and negative acute stage tests that were performed can be found in Figure 3.

- **Chronic stage tests**: IIF was ordered in 121 (37.6%) cases, ELISA in 113 (35.1%), HAI in 56 (17.4%), CFT in 30 (9.3%), IB in 24 (7.5%), RIPA in 8 (2.5%), ICT in 7 (2.2%), and CMIA in 6 (1.9%). Testing techniques were not specified in 76 (23.6%) cases. The proportion of positive and negative chronic stage tests that were performed can be found in Figure 4.

Imaging studies
The most common imaging studies by stage and substage of the disease were:

- **Acute stage**: ECG was ordered in 43 (47.8%) cases, echocardiogram in 37 (41.1%), chest X-ray in 21 (23.3%), head CT in 7 (7.8%), abdominal ultrasound in 6 (6.7%), abdominal X-ray in 3 (3.3%), abdominal CT in 2 (2.2%), and barium swallow, barium enema, and endoscopy in 1 (1.1%).

- **Chronic stage**: ECG was ordered in 21 (70.0%) cases, echocardiogram in 10 (33.3%), chest X-ray in 5...
Table 2. Frequency of clinical manifestations described in the Chagas Disease case reports.

| Body system | Clinical manifestations | Acute | Chronic indeterminate | Chronic determinate | Digestive | Cardio digestive | Reactivation |
|-------------|------------------------|-------|------------------------|---------------------|----------|-----------------|-------------|
|             |                        | n 90  | n 30  % (CI)           | n 82  % (CI)        | n 19  % (CI) | n 17  % (CI)    | n 84  % (CI) |
| General     | Dizziness              | 2     | 60.0 [0.0–0.0]         | 11 13.4 [6.9–22.7]  | 1 5.3 [0.1–26.0] | 2 11.8 [1.5–36.4]  | 3 3.6 [0.7–10.1] |
|             | Fatigue                | 14    | 15.6 [8.8–24.7]        | 8 9.8 [4.3–18.3]    | 0 0.0 [0.0–0.0]  | 2 11.8 [1.5–36.4]  | 9 10.7 [5.0–19.4] |
|             | Weakness               | 5     | 5.6 [1.8–12.5]         | 2 2.4 [0.3–8.5]     | 1 5.3 [0.1–26.0] | 1 5.9 [0.1–28.7]  | 6 7.1 [2.7–14.9] |
|             | Asthenia               | 15    | 16.7 [9.6–26.0]        | 3 3.7 [0.8–10.3]    | 0 0.0 [0.0–0.0]  | 1 5.9 [0.1–28.7]  | 6 7.1 [2.7–14.9] |
|             | Adynamia               | 0     | 0.0 [0.0–0.0]          | 3 3.7 [0.8–10.3]    | 1 5.3 [0.1–26.0] | 0 0.0 [0.0–0.0]  | 2 2.4 [0.3–8.3]  |
|             | Myalgia                | 22    | 24.4 [16.0–34.6]       | 1 3.3 [0.1–17.2]    | 1 1.2 [0.0–6.6]  | 0 0.0 [0.0–0.0]  | 1 5.9 [0.1–28.7]  | 0 0.0 [0.0–0.0]  |
|             | Arthralgia             | 4     | 4.4 [1.2–11.0]         | 2 6.7 [0.8–22.1]    | 2 2.4 [0.3–8.5]  | 0 0.0 [0.0–0.0]  | 0 0.0 [0.0–0.0]  | 0 0.0 [0.0–0.0]  |
|             | Fever                  | 63    | 70.0 [59.4–79.2]       | 7 8.5 [3.5–16.8]    | 1 5.3 [0.1–26.0] | 1 5.9 [0.1–28.7]  | 47 56.0 [44.7–66.8] |
|             | Headache               | 23    | 25.6 [16.9–35.8]       | 3 3.7 [0.8–10.3]    | 1 5.3 [0.1–26.0] | 0 0.0 [0.0–0.0]  | 20 23.8 [15.2–34.3] |
|             | LNE                    | 16    | 17.8 [10.5–27.3]       | 2 2.4 [0.3–8.5]     | 0 0.0 [0.0–0.0]  | 0 0.0 [0.0–0.0]  | 5 6.0 [2.0–13.3]  |
|             | Edema                  | 26    | 28.9 [19.8–39.4]       | 27 32.9 [22.9–44.2] | 0 0.0 [0.0–0.0]  | 4 23.5 [6.8–49.9] | 13 15.5 [8.5–25.0] |
|             | Weight loss            | 3     | 3.3 [0.7–9.4]          | 2 2.4 [0.3–8.5]     | 5 26.3 [9.1–51.2] | 1 5.9 [0.1–28.7]  | 16 19.0 [11.3–29.1] |
|             | Diaphoresis            | 2     | 2.2 [0.3–7.8]          | 0 0.0 [0.0–0.0]     | 3 3.7 [0.8–10.3] | 0 0.0 [0.0–0.0]  | 0 0.0 [0.0–0.0]  | 0 0.0 [0.0–0.0]  |
|             | Dehydration            | 3     | 3.3 [0.7–9.4]          | 0 0.0 [0.0–0.0]     | 0 0.0 [0.0–0.0]  | 4 21.1 [6.1–45.6] | 0 0.0 [0.0–0.0]  | 1 1.2 [0.0–6.5]  |
| Respiratory | Dyspnea                | 20    | 22.2 [14.1–32.2]       | 44 53.7 [42.3–64.7] | 1 5.3 [0.1–26.0] | 6 35.3 [14.2–61.7] | 19 22.6 [14.2–33.0] |
|             | Orthopnea              | 4     | 4.4 [1.2–11.0]         | 23 28.0 [18.7–39.1] | 0 0.0 [0.0–0.0]  | 4 23.5 [6.8–49.9] | 12 14.3 [7.6–23.6] |
|             | PND                    | 5     | 5.6 [1.8–12.5]         | 4 20.7 [12.6–31.1]  | 0 0.0 [0.0–0.0]  | 1 5.9 [0.1–28.7]  | 13 15.5 [8.5–25.0] |
|             | Tachypnea              | 9     | 10.0 [4.7–18.1]        | 4 4.9 [1.3–12.0]    | 1 5.3 [0.1–26.0] | 1 5.9 [0.1–28.7]  | 5 6.0 [2.0–13.3]  |
|             | Cough                  | 8     | 8.9 [3.9–16.8]         | 1 3.3 [0.1–17.2]    | 7 8.5 [3.5–16.8] | 1 5.3 [0.1–26.0] | 1 5.9 [0.1–28.7]  | 4 4.8 [1.3–11.7]  |
|             | Crackles               | 2     | 2.2 [0.3–7.8]          | 0 0.0 [0.0–0.0]     | 12 14.6 [7.8–24.2] | 2 10.5 [1.3–33.1] | 2 11.8 [1.5–36.4] | 5 6.0 [2.0–13.3]  |
| Body system      | Clinical manifestations | Acute n 90 % (CI) | Chronic indeterminate n 30 % (CI) | Chronic determinate Cardiac n 82 % (CI) | Digestive n 19 % (CI) | Cardio digestive n 17 % (CI) | Reactivation n 84 % (CI) |
|------------------|-------------------------|-------------------|-----------------------------------|----------------------------------------|-----------------------|----------------------------|----------------------------|
| Cardiovascular   | Syncope                 | 0 [0.0–0.0]       | 0 [0.0–0.0]                       | 21 [25.6–36.4]                        | 0 [0.0–0.0]           | 4 [23.5–49.9]               | 1 [1.2–6.5]                |
|                  | Palpitations            | 6 [6.7–13.9]      | 0 [0.0–0.0]                       | 26 [31.7–21.9]                        | 0 [0.0–0.0]           | 3 [17.6–43.4]               | 14 [16.7–26.4]             |
|                  | Chest pressure          | 12 [13.3–22.1]    | 0 [0.0–0.0]                       | 35 [42.7–31.8]                        | 1 [5.3–26.0]          | 4 [23.5–49.9]               | 16 [19.0–29.1]             |
|                  | JVD                     | 7 [7.8–15.4]      | 0 [0.0–0.0]                       | 24 [29.3–19.7]                        | 0 [0.0–0.0]           | 3 [17.6–43.4]               | 13 [15.5–25.0]             |
|                  | Bradycardia             | 0 [0.0–0.0]       | 0 [0.0–0.0]                       | 10 [12.2–6.0]                         | 0 [0.0–0.0]           | 0 [0.0–0.0]                 | 1 [1.2–6.5]                |
|                  | Tachycardia             | 16 [17.8–27.3]    | 1 [3.3–17.2]                      | 10 [12.2–6.0]                         | 2 [10.5–33.1]         | 1 [5.9–28.7]                | 11 [13.1–22.2]             |
|                  | Heart murmur            | 5 [5.6–12.5]      | 0 [0.0–0.0]                       | 16 [19.5–11.6]                        | 0 [0.0–0.0]           | 4 [23.5–49.9]               | 1 [1.2–6.5]                |
|                  | Irregular pulse         | 1 [1.1–6.0]       | 0 [0.0–0.0]                       | 6 [7.3–2.7]                           | 0 [0.0–0.0]           | 1 [5.9–28.7]                | 1 [1.2–6.5]                |
|                  | HBP                     | 0 [0.0–0.0]       | 2 [6.7–22.1]                      | 9 [11.0–19.8]                         | 0 [0.0–0.0]           | 3 [17.6–43.4]               | 2 [2.4–8.3]                |
| Gastrointestinal | Hyporexia               | 9 [10.0–18.1]     | 0 [0.0–0.0]                       | 1 [1.2–6.6]                           | 0 [0.0–0.0]           | 1 [5.9–28.7]                | 3 [3.6–10.1]               |
|                  | Nausea                  | 7 [7.8–15.4]      | 0 [0.0–0.0]                       | 3 [3.7–10.3]                          | 3 [15.8–39.4]         | 2 [11.8–36.4]               | 4 [4.8–11.7]               |
|                  | Vomiting                | 9 [10.0–18.1]     | 1 [3.3–17.2]                      | 5 [6.1–2.0]                           | 3 [15.8–39.4]         | 2 [11.8–36.4]               | 6 [7.1–14.9]               |
|                  | Dysphagia               | 0 [0.0–0.0]       | 0 [0.0–0.0]                       | 5 [6.1–2.0]                           | 7 [36.8–61.6]         | 4 [23.5–49.9]               | 4 [4.8–11.7]               |
|                  | Regurgitation           | 0 [0.0–0.0]       | 0 [0.0–0.0]                       | 1 [1.2–6.6]                           | 3 [15.8–39.4]         | 0 [0.0–0.0]                 | 1 [1.2–6.5]                |
|                  | Abdominal pain          | 16 [17.8–27.3]    | 1 [3.3–17.2]                      | 1 [1.2–6.6]                           | 6 [31.6–56.6]         | 5 [29.4–56.0]               | 3 [3.6–10.1]               |
|                  | Distention              | 4 [4.4–11.0]      | 0 [0.0–0.0]                       | 2 [2.4–8.5]                           | 5 [26.3–51.2]         | 4 [23.5–49.9]               | 0 [0.0–0.0]                |
|                  | Constipation            | 0 [0.0–0.0]       | 1 [3.3–17.2]                      | 3 [3.7–10.3]                          | 14 [73.7–89.9]        | 7 [41.2–67.1]               | 0 [0.0–0.0]                |
|                  | Diarrhea                | 3 [3.3–9.4]       | 0 [0.0–0.0]                       | 0 [0.0–0.0]                           | 0 [0.0–0.0]           | 0 [0.0–0.0]                 | 5 [6.0–13.3]               |
|                  | Ascites                 | 4 [4.4–11.0]      | 0 [0.0–0.0]                       | 1 [1.2–6.6]                           | 0 [0.0–0.0]           | 0 [0.0–0.0]                 | 0 [0.0–0.0]                |
|                  | Hepatomegaly            | 23 [25.6–35.8]    | 2 [6.7–22.1]                      | 7 [8.3–16.8]                          | 0 [0.0–0.0]           | 1 [5.9–28.7]                | 8 [9.5–17.9]               |
|                  | Splenomegaly            | 11 [12.2–20.8]    | 3 [10.0–26.5]                     | 2 [2.4–8.5]                           | 0 [0.0–0.0]           | 0 [0.0–0.0]                 | 1 [1.2–6.5]                |
The list of abnormal findings described in chest X-rays (Table S1), ECGs (Table S2), echocardiograms (Table S3), abdominal X-rays (Table S4), barium swallows (Table S5), barium enemas (Table S6), abdominal ultrasounds (Table S7), abdominal CTs (Table S8), endoscopies (Table S9), colonoscopies (Table S10), and head CTs (Table S11) by stage and substage of the disease can be consulted in the supplementary material.

### Stages of the disease

Of the 322 cases, 90 (28.0%) were diagnosed during the acute stage of the disease while 232 (72.0%) were diagnosed during the chronic stage.
Of the chronic stage cases, 30 (9.3%) had the chronic indeterminate stage, 118 (36.6%) the chronic determinate stage, and 84 (26.1%) had a reactivation of the disease. From the cases that had the chronic determinate stage, 82 (25.5%) developed the cardiac form, 19 (5.9%) the digestive form, and 17 (5.3%) the cardiodigestive form.

**Figure 3.** Results of the acute stage tests described in the CD case reports.

**Figure 4.** Results of the chronic stage tests described in the CD case reports.

*Figure 3.* Results of the acute stage tests described in the CD case reports.

*Figure 4.* Results of the chronic stage tests described in the CD case reports.

CFT, complement fixation test; CMIA, chemiluminescent microparticle immunoassay; ELISA, enzyme-linked immunosorbent assay; HAI, hemagglutination inhibition assay; IB, immunoblot; ICT, immunochromatographic test; IIF, indirect immunofluorescence; RIPA, radioimmunoprecipitation assay.

**Management of the disease**

Trypanocidal drug treatment was administered in 182 (56.2%) cases, and it was deferred, not offered, or rejected in 140 (43.8%). From the cases who received a trypanocidal drug, 140 (76.9%) received benznidazole, 41 (22.5%) received nifurtimox, and in 1 (0.6%) case, the
trypanocidal drug was not specified. Trypanocidal
drug treatment was started during the acute stage
of the disease in 71 (39.0%) cases and during the
chronic stage in 111 (60.9%). Surgery was per-
formed in 70 (21.7%) cases to treat complica-
tions of the disease.

Histopathologic studies
Histopathology was performed in 126 (39.1%)
cases and not performed in 196 (60.9%). When
performed, the presence of amastigotes was
detected in 81 (64.3%) of the cases and it was
undetected in 45 (35.7%). When detected, 73
(90.1%) cases had the presence of amastigotes in
one organ, 5 (6.2%) in two organs, and 3 (3.7%)
in three organs. In total, amastigotes were iden-
tified in 92 (73.0%) different histopathologic spec-
imens, from which 29 (31.5%) were from the
heart, 26 (28.3%) from the brain, 16 (17.4%) from
the skin, 6 (7.5%) from the esophagus, 4
(4.3%) from the colon and placenta, 2 (2.2%)
from the larynx, and 1 (1.1%) from the bone mar-
row, eyes, stomach, kidneys, and cervix.

Outcome
From the 322 cases, 88 (27.3%) [confidence
interval (CI) 95% (22.5–32.5)] patients died. Of
them, 22 (25.0%) (16.4–35.4) were in the acute
stage of the disease, and 66 (75.0%) (64.6–83.6)
in the chronic stage. The mortality rate was
24.4% (16.0–34.6) for the acute stage cases, and
28.4% (22.7–34.7) for the chronic stage cases.
From the cases that were at the chronic stage, 2
(3.0%) (0.4–10.5) had the chronic indeterminate
stage, 21 (31.8%) (20.9–44.4) the chronic deter-
minate stage, and 43 (65.2%) (52.4–76.5) had a
reactivation of the disease. The mortality rate was
6.7% (0.8–22.1) for the chronic indeterminate
cases, 27.1% (19.3–36.1) for the chronic deter-
minate cases, and 51.2% (40.0–62.3) for the
cases that had a reactivation of the disease. Of
those who were in the chronic determinate stage,
16 (76.2%) (52.8–91.8) had the cardiac form, 1
(4.8%) (0.1–23.8) the digestive form, and 4
(19.0%) (5.4–41.9) had the cardio digestive form.
The mortality rate was 19.5% (11.6–29.7) for the
cardiac form, 5.3% (0.1–26.0) for the digestive
form, and 23.5% (6.8–49.9) for the cardio diges-
tive form.

The most common causes of death by stage and
substage of the disease can be found in Table 3.

Discussion

Epidemiology
The WHO has estimated that between 6 and 8
million people live with CD and that there are
between 65 and 100 million people at risk of
acquiring the disease.5 Each year, approximately
30,000 new cases and nearly 12,000 deaths are
reported in the Americas.6 The Global Burden of
Disease Study 2019 estimated that it is responsi-
ble for 275,000 disability-adjusted life years due
to its substantial morbidity and premature mor-
tality.7 CD is endemic to 21 Latin American
countries.8 However, globalization has led to sub-
sequent migration of infected individuals and
vectors to non-endemic countries.9 According to
our review, most of the individuals who acquired
the disease came from endemic countries. Despite
this, several of them were diagnosed in non-
endemic countries. This situation highlights the
problem of patients traveling around the globe
without knowing their health status. Interestingly,
the autochthonous transmission has been reported
in non-endemic countries, including the US,
which now has native triatomines throughout the
southern states.1 CD is becoming a worldwide
health problem.

Mechanism of transmission
CD is caused by a parasite named T. cruzi, an
obligate, intracellular protozoan with high genetic
and phenotypic diversity. CD is primarily a vec-
tor-borne disease, but it can also be transmitted
through blood transfusions, bone marrow, or
organ transplants, from an infected pregnant
mother to her child, by ingestion of contaminated
food or drinks, and by accidental exposure.10 In
our review, we found that 6 out of 10 patients did
not know how they acquired the disease. This is
common, because triatomines take blood meals
at night undetected. We also read some cases in
which people reported having triatomines as pets. A
lack of awareness, poor hygienic habits, cohabita-
tion with animals, and poor house dwelling qual-
ity are considered the main risk factors for
acquiring the disease.11
Table 3. Causes of death as described in the Chagas Disease case reports.

| Causes of death                      | Acute | Chronic indeterminate | Chronic determinate | Reactivation |
|-------------------------------------|-------|-----------------------|---------------------|--------------|
|                                     | n 22  | % (CI)                | n 2     | % (CI) | n 16 | % (CI) | n 1 | % (CI) | n 4 | % (CI) | n 43 | % (CI) |
| Acute respiratory failure           | 3     | 13.6 [2.9–34.9]       | 0       | 0.0 (0.0–0.0) | 0   | 0.0 (0.0–0.0) | 0   | 0.0 (0.0–0.0) | 2   | 4.7 [0.6–15.8] |
| Arrhythmia                          | 0     | 0.0 (0.0–0.0)         | 0       | 0.0 (0.0–0.0) | 0   | 0.0 (0.0–0.0) | 0   | 0.0 (0.0–0.0) | 1   | 2.3 [0.1–12.3] |
| Cancer-related complications        | 0     | 0.0 (0.0–0.0)         | 1       | 50.0 [1.3–98.7] | 1   | 100 [100.0–100.0] | 0   | 0.0 (0.0–0.0) | 2   | 4.7 [0.6–15.8] |
| Cardiogenic shock                   | 1     | 4.5 [0.1–22.8]        | 0       | 0.0 (0.0–0.0) | 0   | 0.0 (0.0–0.0) | 0   | 0.0 (0.0–0.0) | 2   | 4.7 [0.6–15.8] |
| Cardiopulmonary arrest              | 1     | 4.5 [0.1–22.8]        | 0       | 0.0 (0.0–0.0) | 4   | 25.0 [7.3–52.4] | 0   | 0.0 (0.0–0.0) | 1   | 25.0 [0.6–80.6] | 1   | 2.3 [0.1–12.3] |
| Catatonia                           | 1     | 4.5 [0.1–22.8]        | 0       | 0.0 (0.0–0.0) | 0   | 0.0 (0.0–0.0) | 0   | 0.0 (0.0–0.0) | 0   | 0.0 (0.0–0.0) | 0   | 0.0 (0.0–0.0) |
| Cerebrovascular infarction          | 0     | 0.0 (0.0–0.0)         | 0       | 0.0 (0.0–0.0) | 2   | 12.5 [1.6–38.3] | 0   | 0.0 (0.0–0.0) | 0   | 0.0 (0.0–0.0) | 0   | 0.0 (0.0–0.0) |
| Heart failure                       | 3     | 13.6 [2.9–34.9]       | 0       | 0.0 (0.0–0.0) | 1   | 6.3 [0.2–30.2] | 0   | 0.0 (0.0–0.0) | 1   | 25.0 [0.6–80.6] | 1   | 2.3 [0.1–12.3] |
| Heart infarction                    | 0     | 0.0 (0.0–0.0)         | 0       | 0.0 (0.0–0.0) | 1   | 6.3 [0.2–30.2] | 0   | 0.0 (0.0–0.0) | 0   | 0.0 (0.0–0.0) | 0   | 0.0 (0.0–0.0) |
| Hydrops fetalis                     | 1     | 4.5 [0.1–22.8]        | 0       | 0.0 (0.0–0.0) | 0   | 0.0 (0.0–0.0) | 0   | 0.0 (0.0–0.0) | 0   | 0.0 (0.0–0.0) | 0   | 0.0 (0.0–0.0) |
| Intraconal hemangioma               | 0     | 0.0 (0.0–0.0)         | 0       | 0.0 (0.0–0.0) | 0   | 0.0 (0.0–0.0) | 0   | 0.0 (0.0–0.0) | 1   | 2.3 [0.1–12.3] |
| Intracranial bleeding               | 0     | 0.0 (0.0–0.0)         | 0       | 0.0 (0.0–0.0) | 0   | 0.0 (0.0–0.0) | 0   | 0.0 (0.0–0.0) | 1   | 2.3 [0.1–12.3] |
| Intracranial hypertension           | 0     | 0.0 (0.0–0.0)         | 0       | 0.0 (0.0–0.0) | 0   | 0.0 (0.0–0.0) | 0   | 0.0 (0.0–0.0) | 2   | 4.7 [0.6–15.8] |
| Multiorgan failure                  | 0     | 0.0 (0.0–0.0)         | 0       | 0.0 (0.0–0.0) | 0   | 0.0 (0.0–0.0) | 0   | 0.0 (0.0–0.0) | 7   | 16.3 [6.8–30.7] |
| Myocarditis                         | 1     | 4.5 [0.1–22.8]        | 0       | 0.0 (0.0–0.0) | 1   | 6.3 [0.2–30.2] | 0   | 0.0 (0.0–0.0) | 1   | 2.3 [0.1–12.3] |
| Postoperative complications         | 1     | 4.5 [0.1–2.8]         | 0       | 0.0 (0.0–0.0) | 0   | 0.0 (0.0–0.0) | 0   | 0.0 (0.0–0.0) | 0   | 0.0 (0.0–0.0) | 0   | 0.0 (0.0–0.0) |
| Septic shock                        | 6     | 27.3 [10.7–50.2]      | 1       | 50.0 [1.3–98.7] | 2   | 12.5 [1.6–38.3] | 0   | 0.0 (0.0–0.0) | 1   | 25.0 [0.6–80.6] | 11  | 25.6 [13.5–41.2] |
| Transplant rejection                | 0     | 0.0 (0.0–0.0)         | 0       | 0.0 (0.0–0.0) | 0   | 0.0 (0.0–0.0) | 0   | 0.0 (0.0–0.0) | 2   | 4.7 [0.6–15.8] |
| Unknown                             | 4     | 18.2 [5.2–60.3]       | 0       | 0.0 (0.0–0.0) | 5   | 31.3 [11.0–58.7] | 0   | 0.0 (0.0–0.0) | 1   | 25.0 [0.6–80.6] | 9   | 20.9 [10.0–36.0] |

CI, confidence interval.
Regarding other less common routes of transmission, such as blood transfusions and bone marrow or organ transplants, many non-endemic countries have recently added screening of the disease to their health protocols,\(^{12}\) including identifying antibodies against *T. cruzi*. However, there are several countries in which pregnant women are not universally screened for CD.\(^{13}\) In one case report, there were three generations of women diagnosed with CD; congenital transmission was suspected between them.\(^{14}\) Screening of the disease during pregnancy must become a public health policy to prevent further transmission.

Other routes of transmission that cannot be prevented through screening are oral transmission and accidental exposure. Oral transmission has been acknowledged as an important route for acquiring CD, leading to a highly severe, acute presentation and can happen in contaminated food outbreaks. The foods that have been associated with this route are vegetables and wild animal meat; meanwhile, the beverages include açaí, babaçu, bacaba, ‘comou’, guava, and orange juice, sugar cane, and palm wine.\(^{15}\) We identified that açaí and bacaba juice were the beverages responsible for half of the cases. However, we could not determine which food or beverage were involved in the other half. People should understand the importance of consuming provisions that have passed through washing and pasteurizing processes, as they almost nullify the possibility of acquiring the disease.

Accidental exposure may occur in a laboratory when an unplanned event compromises the handling of specimens that carry viable organisms.\(^{16}\) In theory, people who handle them use personal protective equipment to prevent it and know how to react to exposure. In some cases, the handlers underestimated the accidental exposure or did not report the event to the Department of Occupational Health until clinical manifestations appeared.

**Clinical manifestations**

Clinically, CD can be divided into stages. After the incubation period, which ranges between 7 and 14 days, the host enters the acute stage of the disease, which lasts between 2 and 4 months. At this stage, CD remain asymptomatic in 95% of cases or may present unspecific manifestations in the other 5% of the cases. Among these symptoms are fever, asthenia, adynamia, myalgia, arthralgia, headache, and hepatomegaly or splenomegaly. The Romaña sign and chagomas, which are the hallmarks of the disease, are present in the minority of the cases. Less common symptoms are seizures, altered mental status, and neurological impairment that can be experienced due to CD encephalitis, and dyspnea, chest pressure, and palpitations that can be experienced due to CD myocarditis.\(^{17}\) In our review, we found that 7 out of 10 patients developed fever, that 3 out of 10 had dermatoses, and that 2 out of 10 experienced myalgia, headache, dyspnea, or hepatomegaly. Other clinical manifestations were less commonly observed; by seeing the clinical picture, we can understand why this stage usually goes unnoticed.

Following this stage of disease, the hosts enter the chronic stage of the disease, and depending upon their immunological response; they can remain in the indeterminate stage (70–90%) or may develop the determinate stage (10–30%), in which cardiac, digestive, or cardiodigestive complications are present. CD cardiomyopathy can be characterized by the presence of arrhythmias, conduction system abnormalities, segmental and general contractility abnormalities, progressive congestive heart failure, thromboembolic phenomena, and sudden death; meanwhile, CD megaesophagus can be characterized by the presence of progressive dysphagia that leads to achalasia and increases the risk of regurgitation and bronchoaspiration, and CD megacolon can be characterized by the presence of progressive constipation that increases the risk of fecaloma, volvulus, and bowel ischemia.\(^{18}\) In addition, if the host develops immunosuppression, this can result in reactivation of the disease, in which clinical manifestations related to meningoencephalitis, encephalitis, myocarditis, and panniculitis can appear.\(^{19}\) In our study, we found that only 1 out of 10 patients experienced non-specific symptomatology during the indeterminate stage, which keep them away from seeking medical attention. In contrast, we identified that 5 out of 10 patients developed dyspnea and that 4 out of 10 experienced chest pressure at the chronic determinate stage in its cardiac form; that 7 out of 10 had constipation, and that 3 out of 10 reported having dysphagia and abdominal pain at the chronic determinate stage in its digestive form; and that 4 out of 10 developed constipation and that 3 out of 10 experienced dyspnea at the chronic determinate stage.
in its cardio digestive form. In addition, we identified that 5 out of 10 patients had fever and that 4 out of 10 reported neurological impairment when they had a reactivation of the disease. At this stage, it is possible to identify the body system that has been affected. CD should be considered part of the differential diagnosis in any individual who lives in, or has traveled to, endemic countries and has developed the cardiac, digestive, or cardiodigestive disease, and in any case of encephalitis, myocarditis, or panniculitis in patients with immunosuppression.

**Laboratory testing**

Epidemiological background and clinical manifestations should be considered to make the diagnosis; however, laboratory confirmation is required, and it can be done by multiple methods. Acute CD can be confirmed through direct observation of the parasite in the circulating blood. Simple methods such as fresh blood and blood smear or concentration methods such as Strout test or microhematocrit serve this purpose. Indirect observation can be done by blood culture or xenodiagnoses. In addition, since they need special laboratory requirements and it takes plenty of time to obtain their results, they have fallen into disuse. PCR is an alternative method that has proved its value to diagnose the disease at this stage, especially in congenital cases. In our review, the most frequently performed test for this stage was PCR; coincidently with what has been published in the literature, it was the test that had the highest positive results when performed. However, PCR is not widely available, especially in low-resource settings. In those case scenarios, direct blood examination, blood smear, Strout test, and microhematocrit must remain as the gold standard for diagnosis because they can be easily performed with trained personnel and basic laboratory equipment. Blood culture and xenodiagnoses shall remain only as complementary methods.

On the other hand, chronic CD can be confirmed by detecting antibodies of *T. cruzi* in the blood. This can be conducted using ELISA, IIF, or HAI. Each of these methods has high sensitivity and sensibility. According to the WHO and the Pan American Health Organization (PAHO), two positive results with two different serologic methods are needed to confirm a diagnosis of CD. Other methods, such as CMIA, CFT, ICT, RIPA, and IB, are useful, but have limited clinical utility, are mainly used for research, or are not commercially available. In our review, the most frequently performed tests for this stage were IIF, ELISA, and HAI, as expected according to the current guidelines. Regarding the other serologic tests, IB was mainly performed in research facilities, and CMIA, CFT, ICT, and RIPA were primarily used in older cases. All the tests that were performed at this stage yielded positive results when performed. However, no test should be taken into consideration by itself.

**Imaging testing**

Once the diagnosis is confirmed, patients must be entirely assessed by a transdisciplinary team to identify if there are any disease-related complications. At least an ECG must be performed on every patient to rule out cardiac involvement. If an abnormality is detected at the ECG, echocardiography, chest X-rays, 24-h Holter monitoring, exercise stress testing, electrophysiologic studies, nuclear medicine testing, cardiac magnetic resonance imaging (MRI), or cardiac catheterization and coronary angiography may be practiced according to the underlying symptomatology. We found that an ECG was ordered in 4 out of 10 patients during the acute stage of the disease. The complimentary cardiovascular assessment was performed in 4 out of 10 patients with an echocardiogram and in 2 out of 10 patients with a chest X-ray. The main abnormalities found were changes in repolarization, pericardial effusion, and cardiac enlargement, respectively. On the other hand, regardless of the chronic form of the disease, we observed that an ECG was ordered in 6 out of 10 patients during the chronic stage. The complimentary cardiovascular assessment was performed in 5 out of 10 patients with an echocardiogram and in 3 out of 10 with a chest X-ray. The main abnormalities found were right bundle branch block, decreased left ventricular ejection fraction, and cardiac enlargement, respectively. These types of studies were underutilized, but the findings were consistent with what has been described in the literature.

When CD is suspected, barium swallow, manometry, and endoscopy may be performed to rule out esophageal involvement; meanwhile, barium enema or colonoscopy may be practiced to rule out colonic involvement. Other imaging studies such as abdominal X-rays, abdominal CT, and abdominal ultrasound may be requested upon
specific conditions. Each study should be justified and must be performed following the current best practices. In our review, we identified that imaging studies to rule out gastrointestinal involvement were performed in about 1 out of 10 patients during the acute and chronic stages of the disease, which is comprehensive. The main abnormalities found in the esophageal studies were megaesophagus and cardiac narrowing; meanwhile, the most frequently reported abnormalities at the colonic studies were megacolon, megasigma, and megarectum, also consistent with what has been published in the literature.

Furthermore, if central nervous system (CNS) involvement is suspected, a head CT or MRI may be performed. In our study, we found that a head CT was performed in almost 1 out of 10 patients during the acute stage of the disease and in 2 out of 10 during the chronic stage. This is perfectly understandable, because CNS is not as frequently involved as the cardiovascular or gastrointestinal systems, unless immunosuppression occurs. The main finding in this kind of study was the presence of an intracranial mass, which can be related to the formation of abscesses containing trypanosomes.

**Treatment**

The approach to the management and treatment of CD depends upon the patient’s stage of the disease. Trypanocidal drugs, like benznidazole and nifurtimox, are indicated for those who are at the acute stage, or who are at the chronic stage but are asymptomatic and do not have organ damage. They are contraindicated during pregnancy and in patients with hepatic or kidney failure. Nifurtimox is also contraindicated in case of neurological or psychiatric disorders. Their cure rate ranges from 70% to 80% when administered during the acute stage of the disease; meanwhile, it ranges from 6% to 10% when administered during the chronic stage. In our review, about 3 out of 10 patients were at the acute stage of the disease, and 7 out of 10 at the chronic stage. From the patients at the chronic stage of the disease, 1 out of 10 remained in the chronic indeterminate stage, and 5 out of 10 developed the chronic determinate stage. The other 4 out of 10 had a reactivation of the disease due to immunosuppression. Even though the chronic stage is traditionally divided into chronic indeterminate and chronic determinate stages, we decided to maintain the ‘reactivation’ tag by what the authors reported. By this means, these cases can easily be identified. Regarding treatment, 5 out of 10 patients received trypanocidal treatment. It is well known that benznidazole is better tolerated than nifurtimox, and from the patients who received specific drug treatment, benznidazole was preferred over nifurtimox. Most of the cases in which patients did not receive trypanocidal treatment are justified because of the disease’s stage at where they were and the underlying complications that they had. However, we read about many cases in which patients were eligible. In these cases, clinicians did not consider that they should have been administered, clinicians wanted to administer them, but drugs were not currently available, or patients chose not to take them due to the possible side effects. When started, almost 4 out of 10 patients were at the acute stage of the disease and 6 out of 10 at the chronic stage. This highlights an area of opportunity, as the effectiveness of these treatments decreases over time.

The treatment of CD cardiomyopathy consists of the administration of a combination of angiotensin-converting enzyme inhibitors, angiotensin II receptor blockers, anticoagulants, antiarrhythmics, β-blockers, digoxin, and diuretics. Pacemakers and implantable cardiac defibrillators may be needed to treat the presence of arrhythmias and conduction system abnormalities, as well as cardiac bridging and heart transplantation for end-stage heart failure. The treatment of CD megaesophagus consists of the administration of sphincter relaxants (isosorbide dinitrate or nifedipine), pneumatic balloon dilatation, botulinum toxic injections, and surgery if needed. On the other hand, the treatment of CD megacolon consists of the administration of laxatives, colon enemas, and surgery, if required. In our review, we found that two-thirds of the surgeries that were performed were related to cardiovascular complications (from pacemaker implantation to heart transplantation). The other third of the performed surgeries were related to gastrointestinal complications (from esophagectomy to colectomy). In some cases, surgery is the only option available to improve the symptoms of the patients. However, no patient with CD should develop end-stage chronic complications if it is promptly approached.
**Outcome**

CD mortality rate has been estimated between 1.5% and 51%. According to Cucunubá et al., this heterogeneity in the estimates comes from the lack of agreement between the methodologies that have been used to calculate them. In our review, we found out that the mortality rate for the acute stage cases was 24.4%, while for chronic stage cases this was 28.4%. When disaggregated the chronic stage cases, the mortality rate was 6.7% for the chronic indeterminate cases, 27.1% for the chronic determinate cases, and 51.1% for the cases that had a reactivation of the disease. When disaggregated the chronic determinate stage cases, the mortality rate was 19.5% for the cardiac form, 5.3% for the digestive form, and 23.5% for the cardio digestive form. This excess in mortality can be explained because of the nature of the case reports. Controlled patients are not usually published in the literature; meanwhile, patients with complications, and consequently, worse prognoses, are frequently reported. Moreover, we can relate to several deaths during each stage with the congenital transmission, oral transmission, or reactivation of the disease, respectively.

**Limitations**

Our study was performed by assessing the data contained in case reports. These kinds of publications describe the clinical picture of rare diseases or uncommon presentations of common diseases. In the case of CD, those who belong to non-endemic countries are related to their sole presence; meanwhile, those who belong to endemic countries are related to uncommon mechanisms of transmission that lead to uncommon clinical pictures, immunosuppression that leads to reactivation, or advanced disease stages that lead to unfortunate outcomes. These situations should be taken into consideration to understand the overrepresentation of some uncharacteristic features.

**Conclusion**

CD is a parasitic disease endemic to Latin America, with significant relevance in the world due to increasing migration. In our review, besides describing the trends in the medical practice, which have been appointed in each section of the discussion, we observed a couple of problems that are present in most of the cases: people are unaware of the threat that this disease represents for their health and patients travel a long journey from the onset of their symptoms until they are finally diagnosed. Community awareness must be increased to prevent the disease’s acquisition, and health professionals should be trained early in their career to promptly detect and properly treat the current cases. We cannot longer keep missing opportunities to stop the progression of the disease. Furthermore, public health policies must be modified to guarantee the availability of screening and diagnostic tests, the stock of trypanocidal drugs, and, eventually, preventive and therapeutic vaccines. CD must be acknowledged as a serious health problem, and major stakeholders must intervene to ensure that no patient is left behind.

**Acknowledgements**

We thank María-José Díaz-Huízar MD, Alberto- Manuel González-Chávez MD, Mario-Alberto González-Chávez MD, Jorge-Alberto Ascencio-Aragón MD, Yolanda Hernández-Ponce MD, and Emmanuel Estefan-Melgarejo PhD for their participation and support in a previous stage of the study.

**Author contributions**

Conceived and designed the study: DAAH, RGRA; evaluated the studies and extracted the data: DAAH, RGRA, AHO, MAS, LAMJ, RVL; performed the analyses: DAAH, RGRA, AHO, MAS, LAMJ, AM, HGR, RVL; wrote the paper: DAAH, RGRA, AHO, MAS, LAMJ, MW, RM, AM, HGR, RVL, AMFP. All authors revised and approved the final version of the paper.

**Conflict of interest statement**

The authors declare that there is no conflict of interest.

**Funding**

The authors received no financial support for the research, authorship, and/or publication of this article.

**ORCID iDs**

Diego-Abelardo Álvarez-Hernández https://orcid.org/0000-0003-2340-6639
Supplemental material

Supplemental material for this article is available online.

References

1. Lynn MK, Bossak BH, Sandifer PA, et al. Contemporary autochthonous human Chagas disease in the USA. Acta Trop 2020; 205:105361.

2. World Health Organization. Chagas disease (also known as American trypanosomiasis). [Internet], https://www.who.int/news-room/fact-sheets/detail/chagas-disease-(american-trypanosomiasis) (2020, accessed 12 December 2020).

3. Engels D and Zhou XN. Neglected tropical diseases: an effective global response to local poverty-related disease priorities. Infect Dis Poverty 2020; 9:10.

4. PRISMA. Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA). [Internet] Ottawa Hospital Research Institute and University of Oxford, http://www.prisma-statement.org/ (2018, accessed 12 December 2020).

5. Freitas-Lidani KC, Antunes-Andrade F, Bavia L, et al. Chagas disease: from discovery to a worldwide health problem. Front Public Health 2019; 7:166.

6. World Health Organization. General Information - Chagas Disease. [Internet] WHO, https://www.paho.org/es/temas/enfermedad-chagas (2020, accessed 12 December 2020).

7. GBD 2019 Diseases and Injuries Collaborators. Global burden of 369 diseases and injuries in 204 countries and territories, 1990–2019: a systematic analysis for the Global Burden of Disease study 2019. Lancet 2020; 396:1204–1222.

8. Chagas Coalition. Learn More About Chagas Disease. [Internet] WHO, http://www.infochagas.org/en/en-que-paises-hay-chagas (2020, accessed 12 December 2020).

9. Antinori S, Galimberti L, Bianco R, et al. Chagas disease in Europe: a review for the internist in the globalized world. Eur J Intern Med 2017; 43:6–15.

10. Coura JR. The main sceneries of Chagas disease transmission. The vectors, blood and oral transmissions - a comprehensive review. Mem Inst Oswaldo Cruz 2015; 110:277–282.

11. Centers for Disease Control and Prevention. Parasites - American Trypanosomiasis (also known as Chagas Disease). Epidemiology and Risk Factors. [Internet] U.S. Department of Health & Human Services, https://www.cdc.gov/parasites/chagas/epi.html (2019, accessed December 2020).

12. Da Costa-Demaurex C, Cárdenas MT, Aparicio H, et al. Screening strategy for Chagas disease in a non-endemic country (Switzerland): a prospective evaluation. Swiss Med Wkly 2019; 149:w20050.

13. Velasco M, Gimeno-Feliú LA, Molina I, et al. Screening for Trypanosoma cruzi infection in immigrants and refugees: systematic review and recommendations from the Spanish Society of Infectious Diseases and Clinical Microbiology. Euro Surveill 2020; 25:1900393.

14. Plourde PJ, Kadkhoda K and Ndao M. Congenitally transmitted Chagas disease in Canada: a family cluster. CMAJ 2017; 189:1489–1492.

15. Filigheddu MT, Górgolas M and Ramos JM. Orally-transmitted Chagas disease. Med Clin 2017; 148:125–131.

16. Safar EH. Laboratory-acquired blood-borne parasites from accidental exposure. J Arab Soc Med Res 2017; 12:1–5.

17. Álvarez-Hernández DA, Franyuti-Kelly GA, Díaz-López-Silva R, et al. Chagas disease: current perspectives on a forgotten disease. Rev Med Hosp Gen Mex 2018; 81:154–164.

18. Bern C. Chagas disease. N Engl J Med 2015; 373:456–466.

19. Lattes R and Lasala MB. Chagas disease in the immunosuppressed patient. Clin Microbiol Infect 2014; 20:300–309.

20. Balouz V, Agüero F and Buscaglia CA. Chagas disease diagnostic applications: present knowledge and future steps. Adv Parasitol 2017; 97:1–45.

21. Pan American Health Organization. Guidelines for the diagnosis and treatment of Chagas disease. Washington, DC: PAHO, 2019.
22. Pereira-Nunes MC, Acquatella H, Bern C, et al. Chagas cardiomyopathy: an update of current clinical knowledge and management. *Circulation* 2018; 138: 169–209.

23. Pinazo MJ, Lacima G, Elizalde JI, et al. Characterization of digestive involvement in patients with chronic T. cruzi infection in Barcelona, Spain. *PLoS Negl Trop Dis* 2014; 8: 1–7.

24. Carpio A, Romo ML, Parkhouse RME, et al. Parasitic diseases of the central nervous system: lessons for clinicians and policy makers. *Expert Rev Neuro* 2016; 16: 401–414.

25. Álvarez-Hernández DA, Castro-Rico ZL, García-Rodríguez-Arana R, et al. Current treatment of Chagas disease. *Curr Treat Opt Infect Dis* 2020; 12: 438–457.

26. Pinazo MJ, Cañas E, Elizalde JI, et al. Diagnosis, management and treatment of chronic Chagas’ gastrointestinal disease in areas where Trypanosoma cruzi infection is not endemic. *Gastroenterol Hepatol* 2010; 33: 191–200.

27. Cucunubá ZM, Okuwoga O, Basáñez MG, et al. Increased mortality attributed to Chagas disease: a systematic review and meta-analysis. *Parasit Vectors* 2016; 9: 42.